Taliya Lantsman, MD, is a hematology/oncology fellow at Beth Israel Deaconess Medical Center.

 Dr Lee on the Safety Profile of Rinatabart Sesutecan in FRα+ Platinum-Resistant Ovarian Cancer

“There were…a total of 4 CRs, 2 of which are pending confirmation. With the longer duration of follow-up… the median DOR has still not yet been reached. We’re very, very encouraged by the findings so far.”

Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute, discusses results from the dose-expansion cohort B1 of the phase 2 RAINFOL

-01 trial (NCT05579366) evaluating the novel folate receptor alpha (FRα)–targeted antibody-drug conjugate rinatabart sesutecan (Rina-S; PRO1184) for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Videos

Elizabeth Lee, MD, discusses the efficacy of rinatabart sesutecan in patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Dr Lee on the Antitumor Activity of Rinatabart Sesutecan in FRα+ Platinum-Resistant Ovarian Cancer

Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Ovarian Cancer

“At our institution, we give radiation to these patients, which differs from what we saw in RUBY, where radiation was not given. Interestingly enough, none of these patients at time of analysis had disease progression or recurrence.”

Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center, discusses the safety and efficacy of dostarlimab-gxly (Jemperli) plus chemotherapy in patients with advanced endometrial cancer according to findings from a real-world, retrospective, single-institution analysis.

Taliya Lantsman, MD, discusses real-world safety and efficacy data with dostarlimab plus chemotherapy in patients with advanced endometrial cancer.

Taliya Lantsman, MD

Articles

Dr Lee on the Antitumor Activity of Rinatabart Sesutecan in FRα+ Platinum-Resistant Ovarian Cancer

Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Ovarian Cancer